Analysis of RRM1 Expression and Efficacy of Gemcitabine in Advanced Non-small Cell Lung Cancer
-
摘要: 目的 探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）组织中核苷酸还原酶M1(RRM1)的表达水平与吉西他滨联合顺铂化疗疗效及预后的相关性。方法 通过免疫组织化学法检测60例晚期NSCLC患者肺组织中RRM1蛋白表达水平，并与患者的临床特征、吉西他滨联合顺铂化疗的疗效及预后的关系进行分析。结果 RRM1的表达在不同性别间差异有统计学意义（P<0.05)；在不同年龄、组织学类型及分期间差异无统计学意义（P>0.05）。RRM1低表达组的化疗有效率(57.7%)及疾病控制率(69.2%)均高于高表达组（29.4%,35.3%）（P<0.05)。在对生存期的分析中发现RRM1低表达组的生存期(18月)及无疾病进展期(6月)均明显长于高表达组(13月,4月) （P<0.05)，1年生存率(69.2%)及2年生存率(23.1%)均高于高表达组(58.8%,3%)（P<0.05)。结论 晚期非小细胞肺癌组织中RRM1低表达的患者对吉西他滨联合顺铂化疗反应的有效率更高，生存期更长，是独立的预后因素。这将有助于筛选适合接受吉西他滨联合顺铂进行一线化疗的患者。Abstract: Objective To investigate the clinical efficacy and prognostic significance of ribonucleotide reductase M1(RRM1) expression in lung tissue of patients with Non-small cell lung cancer(NSCLC) treated with gemcitabine combined with platinum. Methods Tumor samples obtained from 60 patients with advanced NSCLC were collected to investigate the expression level of RRM1 by the immunohistochemical methods.Relationships between the expression and clinical characters,efficacy,overall survival time of patients with advanced NSCLC were analyzed. Results The RRM1 expression was significant difference between male and female（P＜0.05),while there was no correlation between RRM1 expression and age,pathological type and TNM stage（P＞0.05）.Patients with low expression had remarkably higher response rate (57.7%) and disease control rate(69.2%) to gemcitabine than overexpression RRM1 group（29.4%,35.3%）（P＜0.05).Low expression group of RRM1 had longer overall survival(18 months，13 months),longer progression free survival (6months,4months) and higher 1-year survival rate(69.2%,58.8%),2-year survival rate((23.1%,3%) than over expression group（P＜0.05). Conclusion The patients with low RRM1 expression levels have higher response to chemotherapy and longer survival time.RRM1 expression is an independent prognostic factor.The result of this study may be helpful for selecting patients of advanced NSCLC with low RRM1 expression levels to accept gemcitabine combined with platinum.
-
Key words:
- Non-small cell lung cancer /
- Ribonucleotide reductase M1 /
- Gemcitabine /
- Efficacy /
- Immunohistochemistry
-
-
[1] Cui GJ,Liu ZH,Chen Z,et al.Clinical controlled trial of four chemotherapy regiments for advanced non-small cell lung cancer.[J].Zhong Liu Xue Za Zhi,2006,12(2):136-8.[崔国建,刘振华,陈峥,等.晚期非小细胞肺癌4种化疗方案临床对照 研究[J].肿瘤学杂志,2006,12（2）：136-8.] [2] Bergman AM,Eijk PP,Ruiz van Haperen VW,et al.In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as a major determinant[J].Cancer Res,2005,65(20):9510 -6. [3] Rosell R,Cobo M,Isla D,et al.Phamacogenomics and gemcitabine[J].Ann Oncol,2006,17(Suppl 5):v13-16. [4] Dong S,Wu YL.Research progression of expression level of ribonucleotide reductase M1 gene predict gemcitabine resistance in lung cancer[J].Zhong Liu Yan Jiu Yu Lin Chuang,2006,18(6):426-8.[董嵩，吴一龙.RRM1基因表达水平预测 肺癌对吉西他滨耐药性的研究进展[J].肿瘤研究与临床,2006,18(6):426-8.] [5] Luo Y,Feng FY.Research progression of ribonucleotide reductase subunit M1 and excision repair cross- complementing 1 in non-small cell lung cancer[J].Ai Zheng Jin Zhan,2008,6(2):152-6.[罗扬,冯奉仪.核苷酸还原酶亚单 位M1和内切修复交叉补体1在非小细胞肺癌中的研究进展[J].癌症进展,2008,6(2):152-6.] [6] Chen Q,Zhou CC,Zhang J.Expression and prognostic significant of ERCC1、RRM1 and BRCA1 in non-smallcell lung cancer[J].Zhong Liu,2007,27(9):719-22.[陈芹，周彩存，张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J] .肿瘤,2007,27（9）:719-22.] [7] Rosell R,Scagliotti G,Danenberg KD,et al.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer [J].Oncogene,2003,22(23):3548-53. [8] Bepler G,Kusmartseva I,Shama S,et al.RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer[J].J Clin Oncol,2006,24(29):4731-7. [9] Davidson JD,Ma L,Flagella M,et al.An increase in the expression of ribonucleotide reductase large subunitl is associated with gemcitabine resistance in non-small-cell lung cancer cell lines[J].Cancer Res,2004,64(11):3761-6. [10] Rosell R,Danenberg KD,Alberola V,et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-25. [11] Rosell R,Crino L,Danenberg K,et al.Targeted therapy in combination with gemcitabine in non-small-cell lung cancer[J].Semin Oncol,2003,30(4 Suppl 10):19-25. [12] Liao RQ,Lin JY,Qiao GB,et al.Analysis of prognosis factors for RRM1 expression in non-small cell lung cancer tissue microarray[J].Zhong Guo Fei Ai Za Zhi,2006,9(5):423-7.[廖日强,林嘉颖,乔贵宾,等.非小细胞肺癌组织芯片中RRM1 表达和预后因子分析[J].中国肺癌杂志,2006,9(5]:423-7.]
计量
- 文章访问数: 1613
- HTML全文浏览量: 33
- PDF下载量: 332
下载:
